Investing Profile

Vineeta Agarwala

VCInvestor
General Partner @a16z; Physician @Stanford
a16z.com/author/vineeta-agarw...San Francisco Bay Area
Photo of Vineeta Agarwala, General Partner at Andreessen Horowitz
Your Intro Paths to Vineeta Agarwala

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →

Find Vineeta Agarwala on

cb
Current Investing Position
Andreessen Horowitz General Partner
Investment Range
$10K - $100.0M
Sweet Spot
$10.0M
Investments On Record
31
Current Fund Size
$2.2B

Vineeta Agarwala is on these Sector & Stage Rankings

Vineeta Agarwala's Investments On Record (19)

CompanyStageDateRound SizeTotal Raised
Stipple Bio
Series AApr 2026$100M
$100M
Co-investors: Derek DiRocco (RA Capital Management), Thilo Schroeder (Nextech Invest)
Pomelo Care
Series CJan 2026$92M
Series BJun 2024$46M
Series AJun 2023$33M
$170M
Co-investors: Josh Kopelman (First Round Capital), Aaron Shapiro (Stripes Group)
Gate Bioscience
Series BNov 2025$65M
Series ANov 2023$60M
$130M
Co-investors: Scott Biller (GV (Google Ventures)), Krishna Yeshwant (GV (Google Ventures)), Jay Parrish (ARCH Venture Partners), Clare Ozawa (Versant Ventures)
knownwell
Series BOct 2025$25M
Series ADec 2023$20M
$50M
Co-investors: Ian Chiang (Flare Capital Partners), Varsha Rao (Nurx), Larry Summers
Thyme Care
Series DSep 2025$97M
Series CJul 2024$55M
Series BAug 2023$60M
Series AOct 2021$22M
$230M
Co-investors: Brenton Fargnoli (AlleyCorp), Faraz Rahman (CVS Health Ventures), Vivek Garipalli (Wormhole Capital), David Whelan (Town Hall Ventures), Vijay Patel (CVS Health Ventures), Kurt Sheline (Echo Health Ventures)
Arda Therapeutics
Series AOct 2024$43M
$43M
Co-investors: Rebecca (Becky) Pferdehirt (Andreessen Horowitz), Matthew Caspari (Alumni Ventures ), Konstantin von Unger (Pava Partners)
GC Therapeutics
Series ASep 2024$65M
$65M
Co-investors: Alaa Halawa (Mubadala)
Santa Ana Bio
Series BJun 2024$130M
$170M
Co-investors: Brendan Bulik-Sullivan (GV (Google Ventures)), Sherry Chao (GV (Google Ventures)), Christine Borowski (Access Biotechnology), Peter Emtage (Versant Ventures), Jerel Davis (Versant Ventures), Shinichiro Fuse

most interested in

therapeutics, diagnostics, and digital health, with a focus on companies that are leveraging unique datasets to improve drug development and patient care delivery